scholarly journals Shenqi Fuzheng Injection in the Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials

2018 ◽  
Vol 18 ◽  
pp. 153473541881682 ◽  
Author(s):  
Shuyu Liu ◽  
Dan Zhang ◽  
Jiarui Wu ◽  
Kaihuan Wang ◽  
Yi Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Performance Status ◽  
Cochrane Collaboration ◽  
Effective Rate ◽  
Current Evidence ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Shenqi Fuzheng Injection

Objective: This meta-analysis synthesized the available evidence on the effectiveness and safety of Shenqi Fuzheng injection (SQFZI) combined with chemotherapy for breast cancer. Method: A comprehensive systematic literature search was conducted to identify the randomized controlled trials (RCTs) on breast cancer treated by SQFZI in several electronic database up to October 29, 2017. The included RCTs were assessed using the Cochrane Collaboration tool; data were extracted and analyzed via RevMan 5.3 and Stata 13.0 software. Results: A total of 31 eligible RCTs comprising 2543 participants were selected in this present meta-analysis. The results demonstrated that compared with receiving conventional chemotherapy alone, SQFZI treatment combined with chemotherapy was more efficient in improving clinical total effective rate (relative risk [RR] = 1.31, 95% CI 1.19-1.44, P < .00001) and performance status (RR = 2.23, 95% CI 1.88-2.65, P < .00001). Additionally, SQFZI combined with chemotherapy was capable of enhancing immune function and alleviating adverse drug reactions for patients with breast cancer. Conclusions: The current evidence suggested that using SQFZI as an adjunct treatment to chemotherapy may be preferable for patients with breast cancer compared to chemotherapy alone. Because of the limitations of the quantities and qualities of included RCTs, more well-designed RCTs are needed to further support our conclusion.

scholarly journals Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Yanhong Lv ◽  
Guijuan Zhang ◽  
Yi Ma ◽  
Min Ma ◽  
Rui Liao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Effective Rate ◽  
Bone Marrow Suppression ◽  
Control Group ◽  
Controlled Trials ◽  
Therapeutic Effectiveness ◽  
Randomized Controlled ◽  
Shenqi Fuzheng Injection ◽  
Experimental Group

Purpose.To evaluate the therapeutic effectiveness and safety of shenqi fuzheng injection (SFI) in the associated chemotherapy of breast cancer.Methods. 1247 subjects were included in this study for meta-analysis with RevMan 5.3.Results. The clinical curative effective rate (OR = 2.03, 95% Cl [1.44, 2.86],P<0.0001), grades of KPS (OR = 4.11, 95% Cl [2.74, 6.16],P<0.00001), CD3+cells (MD = 7.05, 95% Cl [0.45, 13.64],P=0.04) and CD4+cells (MD = 8.60, 95% Cl [2.67, 14.54],P=0.004) and CD4/CD8+cells (MD = 0.35, 95% Cl [0.14, 0.56],P=0.001), WBC (OR = 0.30, 95% Cl [0.20, 0.46],P≤0.0001), PLT (OR = 0.36, 95% Cl [0.20, 0.67],P=0.001), gastrointestinal reaction (OR = 0.21, 95% Cl [0.14, 0.32],P<0.00001), and ECG (OR = 0.26, 95% Cl [0.13, 0.51],P<0.0001) in the experimental group were superior to the control group. While there were no differences between two groups in CD8+(MD = 0.21, 95% Cl [−2.81, 3.23],P=0.89), NK+(MD = 1.06, 95% Cl [−9.40, 11.53],P=0.84), RBC (OR = 0.49, 95% Cl [0.14, 1.74],P=0.27), liver function (OR = 0.59, 95% Cl [0.28, 1.24],P=0.16), renal function (OR = 0.56, 95% Cl [0.13, 2.45],P=0.44), and bone marrow suppression (OR = 0.50, 95% Cl [0.25, 1.01],P=0.05).Conclusion. SFI combined with chemotherapy, to some extent, can improve the effectiveness and the security in the treatment of breast cancer; the mechanism may be related to the elevated immunity.

scholarly journals Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for Patients With Advanced Breast Cancer: a Meta-analysis of Randomized Controlled Trials

2020 ◽  
Author(s):  
YongCheng Su ◽  
XiaoGang Zheng
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trials ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Parp Inhibitors ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Increased Risk ◽  
Grade 3

Abstract BACKGROUND: Poly(ADP–ribose) polymerase (PARP) inhibitors are new class of drugs that are currently being studied in several malignancies. However, datas about the efficacy and safety of the PARP inhibitors are limited. Therefore, we conducted a meta-analysis of randomized controlled trials (RCT) in patients with breast cancer.METHODS: Pubmed/Medline, Embase, Cochrane Library, and abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO) were searched for articles published from 2000 to June 2018.Summary incidences and the RR, HR with 95% confidence intervals, were calculated by using a random-effects or fixed-effects model.RESULTS: The summary HR indicated PARPi was not associated with OS (HR=0.83, 95%CI 0.66–1.06, Z=1.49, P=0.14), while it could significantly improve PFS ande time to deterioration (TTD) of global health status/quality of life(GHS/QoL) as compared with traditional standard therapy, the HR was 0.60(95%CI 0.50-0.72; Z=5.52, P＜0.00001) and 0.4 (95%CI 0.29–0.54,z=5.80 ,p=0.000),respectively.The RR of grade 3 or more anemia ,fatigue and headache was 3.02 (95% CI, 0.69–13.17;p = 0.14,,I2=90%),0.77 (95%CI, 0.34–1.73;p=0.52,I2=7%) and 1.13 (95% CI,0.30–4.18;p=0.86,I2=0%),respectively.CONCLUSION: The findings of this meta-analysis showed that PARPi has no significant effect on OS, while it could significantly improve in PFS and TTD of GHS/QoL for patients with advanced or metastatic breast cancer.Furthermore,our findings also demonstrated that the PARPi treatment is connected with an increased risk of grade 3 or more anemia adverse events.

Sign in / Sign up

Export Citation Format

Share Document